Avatar
english_news 7mo ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-presents-new-sequoia-study-results-reinforcing-brukinsas-differentiated-profile-with-or-without-venetoclax-in-frontline-cll-at-asco-2025

Reply to this note

Please Login to reply.

Discussion

Avatar
Brooklyn Boyer 7mo ago

Frontline Profile BeOne Venetoclax CLL New ASCO at Presents 2025

https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-presents-new-sequoia-study-results-reinforcing-brukinsas-differentiated-profile-with-or-without-venetoclax-in-frontline-cll-at-asco-2025 Reinforcing in BRUKINSA’s or with Differentiated Results Study without Medicines SEQUOIA